Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Cannabidiol-from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer.

Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, Paunescu V, Dehelean CA, Ardelean F, Diaconeasa Z, Soica C, Danciu C.

Int J Mol Sci. 2019 Nov 25;20(23). pii: E5905. doi: 10.3390/ijms20235905. Review.

2.

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M.

Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6. Review.

3.

Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer.

Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L.

Biomed Res Int. 2018 Dec 4;2018:1691428. doi: 10.1155/2018/1691428. eCollection 2018. Review.

4.

A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.

Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.

Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35. doi: 10.1007/s00406-019-00978-2. Epub 2019 Jan 19.

PMID:
30661105
5.

Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects.

Eichler M, Spinedi L, Unfer-Grauwiler S, Bodmer M, Surber C, Luedi M, Drewe J.

Planta Med. 2012 May;78(7):686-91. doi: 10.1055/s-0031-1298334. Epub 2012 Mar 12.

PMID:
22411724
6.

Pharmacology of Medical Cannabis.

Amin MR, Ali DW.

Adv Exp Med Biol. 2019;1162:151-165. doi: 10.1007/978-3-030-21737-2_8. Review.

PMID:
31332738
7.

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.

Watt G, Karl T.

Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020. eCollection 2017. Review.

8.

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran HV.

Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34. doi: 10.1016/j.euroneuro.2014.11.014. Epub 2014 Dec 5.

9.

Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z, Zuardi AW, McGuire PK.

Arch Gen Psychiatry. 2009 Jan;66(1):95-105. doi: 10.1001/archgenpsychiatry.2008.519.

PMID:
19124693
10.

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

Deiana S.

Drug Test Anal. 2013 Jan;5(1):46-51. doi: 10.1002/dta.1425. Epub 2012 Oct 25.

PMID:
23109356
11.

A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.

Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T.

Int J Neuropsychopharmacol. 2010 Aug;13(7):861-76. doi: 10.1017/S1461145709990605. Epub 2009 Sep 29.

PMID:
19785914
12.

A systematic review of the antipsychotic properties of cannabidiol in humans.

Iseger TA, Bossong MG.

Schizophr Res. 2015 Mar;162(1-3):153-61. doi: 10.1016/j.schres.2015.01.033. Epub 2015 Feb 7. Review.

PMID:
25667194
13.

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.

Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS.

Psychopharmacology (Berl). 2019 Sep;236(9):2713-2724. doi: 10.1007/s00213-019-05246-8. Epub 2019 May 1.

14.

Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.

Morini L, Porro G, Liso M, Groppi A.

Curr Pharm Biotechnol. 2017;18(10):828-833. doi: 10.2174/1389201019666171129175655.

PMID:
29189144
15.

Is Cannabidiol a Promising Substance for New Drug Development? A Review of its Potential Therapeutic Applications.

Noreen N, Muhammad F, Akhtar B, Azam F, Anwar MI.

Crit Rev Eukaryot Gene Expr. 2018;28(1):73-86. doi: 10.1615/CritRevEukaryotGeneExpr.2018021528. Review.

PMID:
29773016
16.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

17.

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A.

Curr Oncol. 2016 Mar;23(2):S15-22. doi: 10.3747/co.23.2893. Epub 2016 Mar 16.

18.

Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.

Ross HR, Napier I, Connor M.

J Biol Chem. 2008 Jun 6;283(23):16124-34. doi: 10.1074/jbc.M707104200. Epub 2008 Apr 7.

19.

Cannabidiol as potential anticancer drug.

Massi P, Solinas M, Cinquina V, Parolaro D.

Br J Clin Pharmacol. 2013 Feb;75(2):303-12. doi: 10.1111/j.1365-2125.2012.04298.x. Review.

Supplemental Content

Support Center